Innovating Works

ACORN

Financiado
Nanoparticle Based Therapeutic Applications and Detection of Carbon Monoxide Rel...
Nanoparticle Based Therapeutic Applications and Detection of Carbon Monoxide Releasing Molecules Carbon monoxide (CO) has gathered increasing attention because of its role as a gasotransmitter with therapeutic and cell-protective effects. It is also recognised as a cell-signalling molecule where recent developments in the are... Carbon monoxide (CO) has gathered increasing attention because of its role as a gasotransmitter with therapeutic and cell-protective effects. It is also recognised as a cell-signalling molecule where recent developments in the area of CO-releasing molecules (CORMs) and materials for controlled CO application have shown their importance with respect to delivery of such agents to their respective targets. However, despite their promise, their remains two major bottlenecks that may prevent these compounds from reaching the clinic. Firstly, the precise spatial-temporal CO release of CORMs is not target-specific. The CO molecule is highly diffusive and binds to haemoproteins, which are ubiquitous. Secondly, CORMs are made of metal carbonyl complexes and as organometallic compounds, there is the potential of heavy metal toxicity. Moreover, since CORMs are water-soluble they are distributed throughout the body, which can lead to further increased toxicities against healthy tissues. Our project aims to alleviate some of the problems of CORMs by a) developing a method to monitor CO release by MRI and optical imaging; b) reformulate CORMs by encapsulating inside nanomaterials (specifically the FDA approved PLGA as a nanocarrier) and c) provide targeting of the CORMs to their site of delivery by conjugating peptide targeting moieties to the surface of the PLGA nanoparticle. Through the completion of these activities, I;;, supported by its twinning partners, is in the best position to achieve an improved capability to compete for internationally competitive research funding and to access business stakeholders. By claiming its position in research and innovation networks IMM will effectively contribute to research excellence and value creation in health at European level. ver más
28/02/2022
iMM
1M€
Duración del proyecto: 43 meses Fecha Inicio: 2018-07-06
Fecha Fin: 2022-02-28

Línea de financiación: concedida

El organismo H2020 notifico la concesión del proyecto el día 2022-02-28
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
WIDESPREAD-05-2017: Twinning
Cerrada hace 7 años
Presupuesto El presupuesto total del proyecto asciende a 1M€
Líder del proyecto
INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANT... No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5